✦ LIBER ✦

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

✍ Scribed by Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, Volker Heilmann, Matthias Beckmann, Ann Stähler, Christian Jackisch, Michael Hubalek, Barbara Richter, Elmar Stickeler, Holger Eidtmann, Christoph Thomssen, Michael Untch, Kerstin Wollschläger, Tibor Schuster, Gunter von Minckwitz…show all 18hide

Book ID: 120963259
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 279 KB
Volume: 139
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2589-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter randomized phase III trial o

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

✍ Baldini, E; Prochilo, T; Salvadori, B; Bolognesi, A; Aldrighetti, D; Venturini, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB

Sunitinib Plus Paclitaxel Versus Bevaciz

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

✍ Nicholas J. Robert; Mansoor N. Saleh; Devchand Paul; Daniele Generali; Laurent G 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 798 KB

Phase III trial comparing epirubicin/pac

Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamid as first line treatment in metastatic breast cancer: Preliminary results of a German AGO trial

✍ G. von Minckwitz; W. Kuhn; C. Thomssen; M. Untch; Th. Bauknecht; D. Eidtmann; V. 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Bevacizumab plus paclitaxel versus bevac

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

The efficacy of bevacizumab plus paclita

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

✍ Wang, Xuan; Huang, Chun; Li, Man; Gu, Yanjun; Cui, Yanfen; Li, Yan 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 395 KB

Gemcitabine, Epirubicin, and Paclitaxel

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

✍ Seidman, A.D. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB